Data from 2 phase III studies of psoriatic arthritis using tofacitinib, adalimumab shows that a significant meaningful clinical response is achieved in 29-53 days -- why then are we not making go vs no-go decisions with modern biologics at 6-8 weeks? https://t.co/F56P9c3Rb5